Opinion

Video

Emerging Bispecifics in Multiple Myeloma: Real-World Insights and Treatment Strategies

Robert M. Rifkin, MD, FACP, discusses how findings from real-world studies on teclistamab and talquetamab presented at the 66th American Society of Hematology Annual Meeting and Exposition reinforce their efficacy and impact on patient outcomes in relapsed/refractory multiple myeloma while panelists discuss how clinicians should prioritize factors such as patient characteristics and treatment history when selecting the most appropriate bispecific therapy for these patients.

Video content above is prompted by the following:

  1. Findings from real-world studies on teclistamab and talquetamab presented at 66th American Society of Hematology Annual Meeting and Exposition highlighted their efficacy and patient outcomes outside clinical trials. How do these findings align with clinical trial data, and what differences (if any) stand out to you in the real-world setting?
  2. Based on the real-world evidence shared for teclistamab and talquetamab, what factors should clinicians prioritize when selecting the appropriate bispecific therapy for patients with relapsed/refractory multiple myeloma?
Related Videos
5 experts are featured in this series
1 expert is featured in this series.
5 experts are featured in this series
5 experts are featured in this series.
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo